Voluntary nationwide recall: Famotidine (Fresenius – November)

Nov. 2025Pharmacy Updates

Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.

This drug is being recalled because the level of a bacteria component called endotoxin was higher than the acceptable range in one sample. Using a product with elevated endotoxin may cause nonserious reactions such as chills, change in mental status, change in breathing status, fever, increase in body temperature, shivering, and shaking. It may also cause severe reactions such as sepsis and septic shock or may lead to death.

As of Nov. 7, the nonserious reactions mentioned above were reported with one lot. There had been no reports of adverse events related to the second and third lots.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Famotidine or are experiencing any problems that may be related to receiving the product, you should stop using it and talk to your doctor.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Fresenius Kabi USA Quality Assurance at 866-716-2459. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. CST.
  • Visit the FDA website.

Recent Announcements

CME Webinar: Lifestyle Medicine in Practice: Evidence‑Based Strategies for Chronic Disease Care

Please join us for a live, CME-accredited webinar on Wednesday, Sept. 23 from noon to 1 p.m., that will provide an overview on lifestyle medicine. Participants will learn how to integrate six core domains—nutrition, physical activity, sleep, stress management, avoidance of risky substances, and social connection—into routine care using practical tools such as brief counseling, motivational interviewing, and team-based strategies.
Aug. 2026Education/Webinars

CME Webinar: Getting it Right from the Start: Identifying Patient Advanced Care Directives

Please join us for a live, CME-accredited webinar on Thursday, Oct. 15, 2026 that will educate providers on identifying advanced directives and surrogate decision makers on admission.
Aug. 2026Education/Webinars

Watch for a chance to rate your experience with UPMC Health Plan

Watch for a chance to rate your experience with UPMC Health Plan. You may be randomly selected to participate in a 2026 Press Ganey provider satisfaction survey that will begin this month.
Aug. 2026Important Notices